PRN: Research and Markets - Global Multiple Myeloma Drugs Market 2017-2021 with Amgen, Celgene, Johnson & Johnson, Novartis & Takeda Pharmaceuticals Dominating

16/gen/2017 20:10:18 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Research and Markets - Global Multiple Myeloma Drugs Market 2017-2021 with Amgen, Celgene, Johnson & Johnson, Novartis & Takeda Pharmaceuticals Dominating


DUBLIN, Jan 16, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Multiple Myeloma Drugs Market 2017-2021" report to their offering.

Global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma. The report also includes a discussion of the key vendors operating in this market.

According to the report, one of the major drivers for this market is growing demand for biologic therapies. The market has been witnessing a growing demand for biologic therapies, which is expected to drive market growth. Biologic therapy is a treatment that triggers the body's immune system to fight myeloma cells. Biologic therapies boost the immune system cells that identify and attack cancer cells. The demand for targeted therapies is due to its higher efficacy than other conventional therapies, which involves in destroying healthy cells too.

The latest trend gaining momentum in the market is emergence of nanomedicine platform. The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor.

Further, the report states that the growing popularity of CAM is expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking CAM therapies. The increased demand for these therapies is also due to the high cost of multiple myeloma therapeutics.

Key vendors

  • Amgen
  • Celgene
  • Johnson & Johnson
  • Novartis
  • Takeda Pharmaceuticals

Other prominent vendors

  • AB Science
  • AbbVie
  • Bristol-Meyer Squibb
  • Celldex Therapeutics
  • Eureka Therapeutics
  • F. Hoffmann-La Roche
  • GlaxoSmithKline
  • ImmunoGen
  • Immunomedics
  • Innate Pharma
  • JW Pharmaceutical
  • Merck
  • Oncolytics Biotech
  • Ono Pharmaceutical
  • Otsuka Pharmaceuticals
  • Prothena Therapeutics
  • Sanofi

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Market research methodology

Part 04: Introduction

Part 05: Disease overview

Part 06: Pipeline analysis

Part 07: Market landscape

Part 08: Market segmentation by therapy

Part 09: Geographical segmentation

Part 10: Market drivers

Part 11: Impact of drivers

Part 12: Market challenges

Part 13: Impact of drivers and challenges

Part 14: Market trends

Part 15: Vendor landscape

Part 16: Key vendor analysis

Part 17: Appendix

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

blog comments powered by Disqus è un servizio offerto da Factotum Srl